HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough breast cancer: targeted drug HLX43 enters phase 2 trial
Disease control Not yet recruitingThis phase 2 trial tests a new drug called HLX43 in 60 people with a common type of advanced breast cancer (HR+ HER2-) that has worsened despite standard hormone therapy. The drug is an antibody-drug conjugate that targets PD-L1 to deliver chemotherapy directly to cancer cells. T…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New imaging tracer could spot hidden cancers
Diagnosis Not yet recruitingThis early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…
Matched conditions: HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC